Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (SNYNF)
OTHER OTC:SNYNF
Holding SNYNF?
Track your performance easily
SNYNF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$86.12 - $121.06
Previous Close$112.03
Volume57.00
Average Volume (3M)7.29K
Market Cap
$144.93B
Enterprise Value$154.68B
Total Cash (Recent Filing)€8.71B
Total Debt (Recent Filing)€18.15B
Price to Earnings (P/E)30.7
Beta0.28
Next Earnings
Oct 25, 2024EPS Estimate
$2.8Last Dividend Ex-Date
May 13, 2024Dividend Yield3.62%
Share Statistics
EPS (TTM)3.65
Shares Outstanding1,252,640,466
10 Day Avg. Volume16,850
30 Day Avg. Volume7,288
Standard Deviation0.06
R-Squared0.10
Alpha0.00500
Financial Highlights & Ratios
Price to Book (P/B)3.78
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$123.83Price Target Upside10.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Sanofi News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessTolebrutinib met the primary endpoint in the Ph3 HERCULES trial by delaying disability progression in patients with nrSPMS, a condition for which there are no approved therapies.
Market PotentialTolebrutinib has blockbuster potential in SPMS despite this being a smaller market because there is no product approved and high medical need.
Stock ValuationSanofi is trading at a 20% discount to the Pharma sector (excluding Novo & Lilly) on 2025e P/E, with earnings growth in line (2024-29e EPS CAGR: +10%).
Bears Say
Clinical TrialsTolebrutinib failed to show superiority over Aubagio in the Ph3 GEMINI 1 and 2 RMS trials.
Financial PerformanceThe revenue beat was partially offset by higher-than-expected total expenses.
Market ExpectationsSome investors anticipate bad news for tolebrutinib due to a competitor’s failure and disappointing financial guidance.
---
Ownership Overview
0.00%
Insiders
12.71% Mutual Funds
14.05% Other Institutional Investors
73.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
SNYNF FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was $86.12 and its highest was $121.06 in the past 12 months.
What is Sanofi’s market cap?
Currently, no data Available
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 25, 2024 which is in 37 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 25, 2024. The company reported $1.918 earnings per share for the quarter, beating the consensus estimate of $1.829 by $0.09.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of $4.17 which represents an annual dividend yield of 3.62%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is $2.8.
How many shares outstanding does Sanofi have?
Sanofi has 1,268,767,800 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $1.918 in its last earnings report, beating expectations of $1.829. Following the earnings report the stock price went up 4.813%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in SNYNF
---
Sanofi Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$123.83 (10.53% Upside)
$123.83 (10.53% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.84%
12-Months-Change
Fundamentals
Return on Equity
5.80%
Trailing 12-Months
Asset Growth
1.69%
Trailing 12-Months
Company Description
Sanofi
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
---
SNYNF Company Deck
---
SNYNF Earnings Call
Q2 2024
0:00 / 0:00
---
SNYNF Stock 12 Month Forecast
Average Price Target
$123.83
▲(10.53% Upside)
Technical Analysis
Best Analysts Covering SNYNF
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+8.54%
reiterated a buy rating 17 days ago
Copying Graham Parry's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +8.54% per trade.
---